CORONA Remedies Limited (BOM:544644)
India · Delayed Price · Currency is INR 1,863.50
+40.85 (2.24%)
At close: Jun 19, 2026
CORONA Remedies Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, CORONA Remedies stock has a consensus rating of "Strong Buy" and an average price target of ₹1,929. The average 1-year stock price forecast is 3.51% higher than the current stock price, while the lowest is ₹1,850 (-0.72%) and the highest is ₹2,047 (+9.85%).
Price Target: ₹1,929 (+3.51%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CORONA Remedies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 |
| Buy | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 3 | 3 | 3 |
Financial Forecast
Revenue This Year
16.44B
from 14.03B
Increased by 17.15%
Revenue Next Year
19.06B
from 16.44B
Increased by 15.96%
EPS This Year
40.88
from 32.67
Increased by 25.10%
EPS Next Year
52.80
from 40.88
Increased by 29.17%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 16.6B | ||
| Avg | 16.4B | ||
| Low | 16.3B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 18.4% | ||
| Avg | 17.1% | ||
| Low | 16.2% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 42.00 | ||
| Avg | 40.88 | ||
| Low | 39.40 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 28.5% | ||
| Avg | 25.1% | ||
| Low | 20.6% |